Exhibit 10.1

SUBSCRIPTION AGREEMENT

September 28, 2012

Insmed Incorporated

9 Deer Park Drive, Suite C,

Monmouth Junction, New Jersey 08852

Ladies and Gentlemen:

The undersigned (the “Investor”), hereby confirms and agrees with you as
follows:

1. This Subscription Agreement (the “Agreement”) is made as of the date hereof
between Insmed Incorporated, a Virginia corporation (the “Company”), and the
Investor.

2. The Company has authorized the sale and issuance to the Investor of
             shares (the “Shares”) of its common stock, par value $0.01 per
share (the “Common Stock”), for a purchase price of $4.07 per share (the
“Purchase Price”).

3. On the date hereof, the Company is offering for sale (the “Offering”) an
aggregate of 6,304,102 shares of its Common Stock, at the Purchase Price, to
certain investors, including the Shares to be offered and sold to the Investor
hereunder. The Company also expects to offer for sale up to an additional $2.0
million of shares of its Common Stock (based on the then most recent
consolidated closing bid price of the Common Stock on the Nasdaq Capital Market)
to an investor, which offering is expected to close on or before October 31,
2012.

4. The offering and sale of the shares of Common Stock in the Offering are being
made pursuant to (1) an effective Registration Statement on Form S-3
(Registration No. 333-182124) (the “Registration Statement”) filed by the
Company with the Securities and Exchange Commission (the “SEC”), which contains
the base prospectus (the “Base Prospectus”) and was declared effective by the
SEC on July 5, 2012, (2) the free writing prospectus delivered to the Investor
on the date hereof, (3) if applicable, each other “free writing prospectus” (as
that term is defined in Rule 405 under the Securities Act of 1933, as amended),
that has been or will be provided to the Investor on or prior to the date hereof
and (4) a final prospectus supplement (the “Prospectus Supplement” and together
with the Base Prospectus, the “Prospectus”) containing certain supplemental
information regarding the Shares and terms of the Offering that will be filed
with the SEC and provided to the Investor along with the Company’s counterpart
to this Agreement or made available to the Investor by the filing by the Company
of an electronic version thereof with the SEC. The Registration Statement, the
documents incorporated by reference therein and all free writing prospectuses
provided to or otherwise made available to Investor at the time of the
Investor’s execution of this Agreement are referred to herein collectively as
the “Disclosure Package.”

5. The Company and the Investor agree that the Investor will purchase from the
Company, and the Company will issue and sell to the Investor, the number of
Shares set forth below for the aggregate purchase price set forth below,
pursuant to and subject to the Terms and Conditions for Purchase of Shares
attached hereto as Annex I, which are incorporated herein by reference as if
fully set forth herein. Unless otherwise requested by the Investor no later than
one business day after the execution of this Agreement by the Investor and
agreed to by the Company, the Shares purchased by the Investor will be delivered
by electronic book-entry at The Depository Trust Company (“DTC”), registered in
the Investor’s name and address as set forth below and will be released by
American Stock Transfer and Trust Company, the Company’s transfer agent (the
“Transfer Agent”), to the Investor at the Closing (as defined in the Terms and
Conditions for Purchase of Shares). The Investor understands and agrees that the
Company, in its sole discretion, reserves the right to accept or reject this
subscription for Shares, in whole or in part.

6. The Investor confirms that it has had full access to all filings made by the
Company with the SEC, including the Disclosure Package (as applicable), and that
it was able to read, review, download and print each such filing prior to or in
connection with the receipt of this Agreement along with the Company’s
counterpart to this Agreement. On or promptly following the date hereof, the
Company will file the Prospectus Supplement with the SEC containing certain
supplemental information regarding the Company and the Offering.

[Remainder of page intentionally left blank. Signature pages follow.]

--------------------------------------------------------------------------------

Number of Shares:            

Aggregate Purchase Price: $        

Please confirm that the foregoing correctly sets forth the agreement between us
by signing in the space provided below for that purpose.

Name of Investor:                                                     

 

By:

 

 

Name:

 

 

Title:

 

 

[Signature Page to Subscription Agreement]

--------------------------------------------------------------------------------

Agreed and accepted on September 28, 2012:

 

Insmed Incorporated

By:

 

 

Name:

 

 

Title:

 

 

[Signature Page to Subscription Agreement]

--------------------------------------------------------------------------------

ANNEX I

TERMS AND CONDITIONS FOR PURCHASE OF SHARES

1. Closings and Delivery of the Shares and Funds.

1.1. Closing. The completion of the purchase and sale of the Shares (the
“Closing”) will occur at a place and time (the “Closing Date”) to be agreed upon
by the Company and the Investor. At the Closing, the Company will cause the
Transfer Agent to deliver to the Investor the number of Shares set forth on the
signature page hereto registered in the name of the Investor or, if so indicated
on the Investor Questionnaire attached hereto as Exhibit A, in the name of a
nominee designated by the Investor.

1.2. Delivery of Funds. Prior to the Closing, the Investor shall remit by wire
transfer the amount of funds equal to the aggregate purchase price for the
Shares being purchased by the Investor to the following account:

 

BANK NAME:   BANK ADDRESS:   ROUTING (ABA) #:   SWIFT CODE:   CREDIT ACCOUNT:  
ACCOUNT NAME:  

1.3. Delivery of Shares. Prior to the Closing, the Investor shall direct the
broker-dealer at which the account or accounts to be credited with the Shares
being purchased by such Investor are maintained, which broker/dealer shall be a
DTC participant, to set up a Deposit/Withdrawal at Custodian (“DWAC”)
instructing the Transfer Agent to credit such account or accounts with the
Shares by means of an electronic book-entry delivery. Such DWAC shall indicate
the settlement date for the deposit of the Shares. Unless the Company and the
Investor agree to an alternative arrangement for payment of the Purchase Price
for the Shares, upon receipt by the Company of the funds pursuant to Section 1.2
above, the Company shall direct the Transfer Agent to credit the Investor’s
account or accounts with the Shares pursuant to the information contained in
such DWAC.

1.5. IT IS THE INVESTOR’S RESPONSIBILITY TO (1) MAKE THE NECESSARY WIRE TRANSFER
OR CONFIRM THE PROPER ACCOUNT BALANCE IN A TIMELY MANNER AND (2) ARRANGE FOR
SETTLEMENT BY WAY OF DWAC IN A TIMELY MANNER. IF THE INVESTOR DOES NOT DELIVER
THE AGGREGATE PURCHASE PRICE FOR THE SHARES OR DOES NOT MAKE PROPER ARRANGEMENTS
FOR SETTLEMENT IN A TIMELY MANNER, THE SHARES MAY NOT BE DELIVERED AT CLOSING TO
THE INVESTOR.

2. Representations, Warranties and Covenants of the Investor

2.1. The Investor represents and warrants to, and covenants with, the Company
that (a) the Investor is knowledgeable, sophisticated and experienced in making,
and is qualified to make decisions with respect to, investments in shares
presenting an investment decision like that involved in the purchase of the
Shares, including investments in securities issued by the Company and
investments in comparable companies, and has requested, received, reviewed and
considered all information it deemed relevant in making an informed decision to
purchase the Shares, (b) the Investor has answered all questions on the
Signature Page and the Investor Questionnaire for use in preparation of the
Prospectus Supplement and the answers thereto are true and correct as of the
date hereof and will be true and correct as of the Closing Date and (c) the
Investor, in connection with its decision to purchase the number of Shares set
forth on the Signature Page, has reviewed the Disclosure Package and is relying
only upon the Disclosure Package and the representations and warranties of the
Company contained herein.

2.2. The Investor further represents and warrants to, and covenants with, the
Company that (a) the Investor has full right, power, authority and capacity to
enter into this Agreement and to consummate the transactions

--------------------------------------------------------------------------------

contemplated hereby and has taken all necessary action to authorize the
execution, delivery and performance of this Agreement, and (b) this Agreement
constitutes a valid and binding obligation of the Investor enforceable against
the Investor in accordance with its terms, except as enforceability may be
limited by applicable bankruptcy, insolvency, reorganization, moratorium or
similar laws affecting creditors’ and contracting parties’ rights generally and
except as enforceability may be subject to general principles of equity
(regardless of whether such enforceability is considered in a proceeding in
equity or at law).

2.3. The Investor understands that nothing in this Agreement, the Prospectus or
any other materials presented to the Investor in connection with the purchase
and sale of the Shares constitutes legal, tax or investment advice. The Investor
has consulted such legal, tax and investment advisors as it, in its sole
discretion, has deemed necessary or appropriate in connection with its purchase
of Shares.

2.4. The Investor represents, warrants and agrees that, since the earlier to
occur of (i) the date on which the Company first contacted such Investor about
the Offering and (ii) the date of this Agreement, it has not engaged in any
transactions in the securities of the Company in violation of securities laws
(including, without limitation, any short sales involving the Company’s
securities). The Investor covenants that it will not engage in any transactions
in the securities of the Company (including short sales) prior to the time that
the transactions contemplated by this Agreement are publicly disclosed. The
Investor agrees that it will not use any of the Shares acquired pursuant to this
Agreement to cover any short position in the Common Stock if doing so would be
in violation of applicable securities laws. For purposes hereof, “short sales”
include, without limitation, all “short sales” as defined in Rule 200
promulgated under Regulation SHO under the Securities Exchange Act of 1934 (the
“Exchange Act”), whether or not against the box, and all types of direct and
indirect stock pledges, forward sales contracts, options, puts, calls, short
sales, swaps, “put equivalent positions” (as defined in Rule 16a-1(h) under the
Exchange Act) and similar arrangements (including on a total return basis), and
sales and other transactions through non-US broker dealers or foreign regulated
brokers.

2.5. Notwithstanding any investigation made by any party to this Agreement, all
covenants, agreements, representations and warranties made by the Investor
herein will survive the execution of this Agreement, the delivery to the
Investor of the Shares being purchased and the payment therefor.

3. Changes. This Agreement may not be modified or amended except pursuant to an
instrument in writing signed by the Company and the Investor.

4. Headings. The headings of the various sections of this Agreement have been
inserted for convenience of reference only and will not be deemed to be part of
this Agreement.

5. Severability. In case any provision contained in this Agreement should be
invalid, illegal or unenforceable in any respect, the validity, legality and
enforceability of the remaining provisions contained herein will not in any way
be affected or impaired thereby.

6. Governing Law. This Agreement will be governed by, and construed in
accordance with, the internal laws of the State of New York, without giving
effect to the principles of conflicts of law that would require the application
of the laws of any other jurisdiction.

7. Counterparts. This Agreement may be executed in two or more counterparts,
each of which will constitute an original, but all of which, when taken
together, will constitute but one instrument, and will become effective when one
or more counterparts have been signed by each party hereto and delivered
(including by fax or electronically) to the other parties.

--------------------------------------------------------------------------------

EXHIBIT A

INSMED INCORPORATED

INVESTOR QUESTIONNAIRE

Pursuant to Section 1 of Annex I to the Agreement, please provide us with the
following information:

 

1. The exact name that your Shares are to be registered in. You may use a
nominee if appropriate:

 

2. The relationship between the Investor and the registered holder listed in
response to item 1 above (if not the same person):

 

3. The mailing address of the registered holder listed in response to item 1
above:

 

4. The Social Security Number or Tax Identification Number of the registered
holder listed in response to item 1 above:

 

5. Name of DTC Participant (broker-dealer at which the account or accounts to be
credited with the Shares are maintained); please include the name and telephone
number of the contact person at the broker-dealer:

 

6. DTC Participant Number:

 

7. Name of Account at DTC Participant being credited with the Shares:

 

8. Account Number at DTC Participant being credited with the Shares: